Skip to content

Dyne Therapeutics

US · DYN #2540 by market cap Listed 2020
15.50 -0.53 -3.31%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 15.91 -0.75%
After-hours 15.50 0.00%
26.7814.2515.502026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on DYN?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -31.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 13.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth B+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 0.0% Better than 24%
Net income CAGR (3Y) 24.6% Better than 77%
Free cash flow CAGR (3Y) 126.7% Better than 95%
Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 39.4% Better than 48%
Operating margin -1.8% Better than 19%
Net margin 1.2% Better than 30%
Return on equity -55.7% Better than 8%
Return on invested capital -52.3% Better than 6%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -40.6% Better than 10%
6-month return -10.8% Better than 39%
12-month return (ex latest month) -26.3% Better than 11%
Distance below 52-week high 43.2% Better than 25%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 22.3x Better than 98%
Debt to assets 14.3% Better than 64%
Interest coverage -71.1x Better than 6%
Free cash flow / net income 475.0% Better than 92%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 90.0% Better than 73%
Upside to average target 125.2% Better than 88%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -9.67%
1M -4.73%
3M -40.34%
6M -11.73%
YTD -20.76%
1Y -22.96%
3Y +45.54%
5Y -1.84%

Key statistics

Price & volume

Prev close
16.03
Open
15.91
Day range
15.41 - 16.48
Avg price
15.74
Volume
2.23M
Turnover
35.12M
Amplitude
6.68%
52-week range
14.00 - 27.31

Valuation

P/E
-4.47
P/E (TTM)
-4.28
P/B
3.12
EPS
-3.47
Net profit
-650.23M
Net assets
930.94M

Share structure

Market cap
2.90B
Float cap
2.90B
Shares out
187.39M
Float shares
186.86M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-09-17
52-week range 11% of range
14.00 27.31

43.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+4.50M net over the window

Short interest

Shares short
24.38M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Dyne Therapeutics (DYN)?

Dyne Therapeutics last traded at 15.50. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Dyne Therapeutics's market cap?

About 2.90B.

What is the P/E ratio of Dyne Therapeutics?

The trailing twelve-month P/E is -4.28. The Valuation tab shows it against the stock's own five-year range.

Does Dyne Therapeutics pay a dividend?

Dyne Therapeutics does not currently pay a regular dividend.

Is Dyne Therapeutics a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 34.90, which implies 125.2% upside from the current price. This is not investment advice.

What is Dyne Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Dyne Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Dyne Therapeutics discussion 0 comments

Add a comment